The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

WST West Pharmaceutical Services, Inc.

Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life ...

Coloplast's current valuation doesn't offer a compelling risk/reward trade-off today, despite high-quality growth potential.

Kepler Capital analyst Maja Pataki maintained a Hold rating on Coloplast A/S (0QBO – Research Report) on January 10 and set a price target of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved. Distribution ...

In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year ...